In addition to print materials, Immunize.org periodically records live webinars and produces or shares short educational videos related to immunization. These webinars and videos reflect current information at the time they were recorded.
Dr. Kelly Moore answers “What is pneumococcal serotype 4 and when might it be considered when selecting a pneumococcal conjugate vaccine product for adults?”
Dr. Kelly Moore discusses “Some children in my practice started the pneumococcal vaccine series with the 13-valent pneumococcal conjugate vaccine, PCV13. Now that PCV15 or PCV20 are recommended, do I need to restart the vaccination series or give additional vaccine doses to all of them?”
Dr. Kelly Moore discusses “How do we account for the history of receipt of Prevnar (the original 7-valent pneumococcal conjugate vaccine) when determining the pneumococcal vaccination needs of an older teen or adult with a high-risk condition?”
Kelly Moore answers the question: My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now?
Dr. Kelly Moore answers the question, “My patient is 80 and had a dose of pneumococcal polysaccharide vaccine, abbreviated PPSV23, at age 65. He has never had a pneumococcal conjugate vaccine (or PCV). What is due now?”
Dr. Kelly Moore answers the question, “Why did ACIP shift the age for routine pneumococcal conjugate vaccination of all adults from 65 years down to 50 years in October 2024?”
The Travel Vaccines main page connects you with authoritative travelers’ health information, with a focus on vaccination, from CDC and other expert sources.
The Travel Vaccines main page connects you with authoritative travelers’ health information, with a focus on vaccination, from CDC and other expert sources.
Learn more about Immunize.org’s vaccine-specific pages.
Learn more about Immunize.org’s vaccine-specific pages.
